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Abstract
A non-targeted metabolomics-based approach is presented that enables the study of pathways in response to drug action
with the aim of defining the mode of action of trypanocides. Eflornithine, a polyamine pathway inhibitor, and nifurtimox,
whose mode of action involves its metabolic activation, are currently used in combination as first line treatment against
stage 2, CNS-involved, human African trypanosomiasis (HAT). Drug action was assessed using an LC-MS based non-targeted
metabolomics approach. Eflornithine revealed the expected changes to the polyamine pathway as well as several
unexpected changes that point to pathways and metabolites not previously described in bloodstream form trypanosomes,
including a lack of arginase activity and N-acetylated ornithine and putrescine. Nifurtimox was shown to be converted to a
trinitrile metabolite indicative of metabolic activation, as well as inducing changes in levels of metabolites involved in
carbohydrate and nucleotide metabolism. However, eflornithine and nifurtimox failed to synergise anti-trypanosomal
activity in vitro, and the metabolomic changes associated with the combination are the sum of those found in each
monotherapy with no indication of additional effects. The study reveals how untargeted metabolomics can yield rapid
information on drug targets that could be adapted to any pharmacological situation.
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Introduction
Human African trypanosomiasis (HAT) is a parasitic infection
in sub-Saharan Africa transmitted by tsetse flies. Its causative
agent is the flagellated protozoan Trypanosoma brucei, with two sub-
species, T. b. gambiense and T. b. rhodesiense responsible for human
disease [1,2].
There are five drugs in use against HAT. Of these five, only
eflornithine has a confirmed mode of action (MOA), namely,
inhibitionofornithine decarboxylase (ODC)[3,4] withconcomitant
perturbation of the polyamine pathway. In addition to the four
licensed drugs, nifurtimox has been recommended by the World
Health Organisation for use against late-stage disease in combina-
tion with eflornithine [5]. The MOA for nifurtimox has, however,
yet to be fully elucidated. For many years it was presumed to exert
its action through the generation of oxidative stress associated with
reduction of the nitro group with subsequent reduction of oxygen to
toxic reactive oxygen species [6,7]. In trypanosomes polyamines
serve an unusual role in combining with glutathione to create the
metabolite trypanothione [8], which carries out many of the cellular
roles usually attributed to glutathione in other cell types, including
protection against oxidative stress. This indicated that eflornithine,
which inhibits polyamine biosynthesis [9,10] and subsequently
trypanothione biosynthesis, would synergise with nifurtimox as
result of a reduced ability of cells to deal with oxidative stress.
However, the data that lead to theconclusionthat nifurtimox causes
oxidative stress is inconclusive [7] and recent evidence shows that
nifurtimox is activated upon metabolism to an open chain nitrile
[11] and that this nitrile is as toxic as the parent drug. In mice there
wasno indicationthat eitherdrug enhanced uptakeof the otherinto
brain [12], indeed eflornithine diminished brain penetration of
nifurtimox in short term uptake assays. Moreover, isobologram
analysis indicated that the two drugs were not synergistic in vitro
[13].
It is very rare for a new chemotherapeutic agent to be licensed
without prior knowledge of its MOA. In 2009, 19 drugs were
approved by the FDA’s centre for drug evaluation and research in
the US, only one of which had a wholly unknown MOA [14]. A
knowledge of the MOA reduces the risk of unexpected toxicity and
allows synergism and resistance mechanisms to be predicted.
Currently, the MOA of a drug is predicted using expensive and
time-consuming enzyme-based assays, followed by targeted
analyses of whether cellular death is associated with changes
consistent with loss of the predicted target.
www.plosntds.org 1 May 2012 | Volume 6 | Issue 5 | e1618Metabolomics is a relatively new technology that enables the
simultaneous identification of hundreds of metabolites within a
given system. In principle, if an enzyme is inhibited by a drug then
the concentration of substrate should rise within a system and the
concentration of product fall. We have recently introduced
metabolomics approaches to investigate metabolism in trypano-
somes [15–19]. Here we use our metabolomics platform to test the
mode of action of eflornithine (an ornithine decarboxylase suicide
inhibitor that has had its MOA validated) and nifurtimox (a drug
for which the MOA is incompletely understood). The combination
therapy was also tested to determine any synergy between the
drugs at the level of metabolism. Broad changes to cellular
metabolomes in response to drug have been determined before
[20–23], and an analysis of the effect of eflornithine along with an
inhibitor of s-adenosyl methionine decarboxylase were studied
using a targeted multi reaction monitoring (MRM) approach in
Plasmodium parasites, responsible for malaria [24] is one of few
studies have focussed on individual changes that can be mapped to
specific targets in the metabolic network. Here we reveal that an
untargeted LC-MS based metabolomics approach identifies
specific changes in the metabolome of trypanosomes that can be
related directly to effects induced by these drugs.
Methods
Trypanosome culture
Bloodstream form trypanosomes were grown in HMI-9
(Biosera) [25] supplemented with 10% foetal calf serum (Biosera),
incubated at 37uC, 5% CO2. Cells for metabolomics assays were
grown in 500 cm
3 Corning vented culture flasks to a maximum
volume of 175 ml per flask. The Alamar blue assay developed by
Raz et al. [26] for bloodstream form trypanosomes was used to
determine activity of drugs against T. brucei strain 427. For
isobologram analyses, alamar blue assays were conducted for one
drug in the presence of three different concentrations (IC50,2 6
IC50 and 0.56IC50) of another drug.
Arginase assays
A commercial kit (QuantiChrom, BioAssay Systems) was used
to measure the arginase activity in cell extracts spectrophome-
trically (Dynex, wavelength 450 nM) by the amount of urea
produced following manufacturers’ specifications.
Uptake assays
A rapid oil/stop spin protocol, previously described by Carter &
Fairlamb [27], was used to determine uptake of radiolabelled
ornithine (4,5-
3H-ornithine, American Radiochemicals). Briefly,
100 ml of oil (1-Bromodo-decane, density: 1.066 g/cm
3) (Aldrich)
and 100 ml, 20 mM, 1% (v/v) radiolabelled ornithine in CBSS
buffer were set up in a tube and 100 ml of cell suspension (10
8 per
mL) for varying lengths of time before stopping the reaction by
centrifugation. Alternatively, radiation was used at 1% (v/v) and
cold ornithine levels were varied, while keeping the incubation
time constant at one minute.
The resulting cell pellet was flash frozen in liquid nitrogen and
the base of the tube containing the pellet was cut into 200 mlo f2 %
SDS in scintillation vials and left for 30 minutes. Three ml of
scintillation fluid was added to each vial and these were left
overnight at room temperature.
Counts per minute were read on a 1450 microbeta liquid
scintillation counter (Perkin Elmer) and normalised between
samples for the cell density. Michaelis-Menten kinetic analyses
were performed using Graphpad Prism 5 software.
Metabolite extraction
Metabolite extraction methods were adapted from Leishmania spp
extraction techniques developed previously [13,28,29]. Cultures
were kept in log phase growth (below 1610
6/ml) in the presence of
drug. At the time of harvest, 4610
7 cells were rapidly cooled to
4uC to quench metabolism by submersion of the flask in a dry ice-
ethanol bath, and kept on ice for all subsequent steps. The cold cell
culture was centrifuged at 1,250 RCF for 10 minutes and the
supernatant completely removed. Cell lysis and protein denatur-
ation was achieved by addition of 200 mLo f4 uC chloroform:-
methanol:water (ratio 1:3:1) plus internal standards (theophylline,
5-fluorouridine, Cl-phenyl cAMP, N-methyl glucamine, canavan-
ine and piperazine, all at 1 mM), followed by vigorous shaking for
1 hour at 4uC. Extract mixtures were centrifuged for two minutes
at 16, 000 RCF, 4uC. The supernatant was collected, frozen and
stored at 280uC under argon until further analysis.
For heavy metabolite tracking analyses, log phase cells were
centrifuged 1,250 RCF for 10 minutes and resuspended in CBSS
(20 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 0.55 mM CaCl2,
0.4 mM MgSO4, 5.6 mM Na2HPO4, 11.1 mM glucose) or HMI-
9 as outlined in the Results section. Heavy atom labelled amino
acids were obtained with
15N incorporation from Cambridge
Isotope Laboratories (L-threonine (98% enrichment, one incor-
poration, alpha-N, cat:NLM-742-0), L-glutamine (98% enrich-
ment, one incorporation, alpha-N, cat: NLM-1016-0), L-arginine
(98% enrichment, four incorporations, allo-N, cat: NLM-396-0),
L-ornithine (98% enrichment, two incorporations, allo-N, cat:
NLM-3610-0), L-lysine (95–99% enrichment, one incorporation,
alpha-N, cat: NLM-143-0)) or Sigma Aldrich (L-proline (98%
enrichment, one incorporation, alpha-N, cat: 608998), L-gluta-
mate (98% enrichment, one incorporation, alpha-N, cat: 332143)).
Quenching of metabolism was achieved through rapid cooling and
metabolite extraction was conducted as above.
Mass spectrometry
Samples were analysed on an Exactive Orbitrap mass
spectrometer (Thermo Fisher) in both positive and negative modes
(rapid switching), coupled to a U3000 RSLC HPLC (Dionex) with
a ZIC-HILIC column (Sequant) as has previously been described
[13]. All samples from an individual experiment were analysed in
the same analytical batch and the quality of chromatography and
signal reproducibility were checked by analysis of quality control
samples, internal standards and total ion chromatograms. The few
Author Summary
Understanding drug mode of action is of fundamental
importance. Of the five drugs in use against human African
trypanosomiasis (HAT), convincing evidence on a specific
mode of action has been proposed only for the polyamine
pathway inhibitor eflornithine. Eflornithine is currently
used with nifurtimox as first line treatment of stage 2 CNS-
involved HAT. Here, we present a new way of determining
the mode of action of a drug by measuring how the levels
of small molecules comprising the cellular metabolome
are perturbed when exposed to drugs. We show that
eflornithine causes the changes in polyamine metabo-
lism previously known to underlie its mode of action.
Furthermore, we show that nifurtimox, is rapidly metab-
olised and significantly alters metabolism. Nifurtimox and
eflornithine do not show the predicted synergy with
regard to trypanocidal activity and this is reflected in
metabolomic analysis where perturbations to the meta-
bolome are additive with no additional changes observed
in the combination.
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time drift) were removed from further analysis. A standard mix
containing approximately 200 metabolites (including members of
the polyamine pathway) was run at the start of every analysis batch
to aid metabolite identification.
Data processing
Untargeted metabolite analysis was conducted with the freely
available software packages mzMatch [30] and Ideom (http://
mzmatch.sourceforge.net/ideom.html). Raw LCMS data was
converted to mzXML format and peak detection was performed
with XCMS [31] and saved in peakML format. MzMatch was
used for peak filtering (based on reproducibility, peak shape and
an intensity threshold of 3000), gap filling and annotation of
related peaks. Ideom was used to remove contaminants and
LCMS artefact peaks and to perform metabolite identification.
Metabolite identities were confirmed by exact mass (after
correction for loss or gain of a proton in negative mode or
positive mode ESI respectively) and retention time for metabolites
where authentic standards were available for analysis, and putative
identification of all other metabolites was made on the basis of
exact mass and predicted retention time of all metabolites from the
KEGG, MetaCyc and Lipidmaps databases [17]. Additional
manual curation was performed on all datasets to confirm the
identification of metabolites that changed significantly in response
to drug treatment, and to remove false-identifications based on the
LCMS meta-data recorded in Ideom. In cases where identification
was putative, the most likely metabolite was chosen based on
available chemical and biological knowledge, however accurate
isomer identification is inherently difficult with LCMS data and
lists of alternative identifications and meta-data for each identified
formula are accessible in the macro-enabled Ideom files (Figure
S1, Figure S2, Figure S3 and Figure S4; help documentation
available at mzmatch.sourceforge.net/ideom.html). Quantification
is based on raw peak heights, and expressed relative to the average
peak height observed in untreated cells from the same experiment.
Unidentified peaks in the LCMS data were also investigated for
drug-induced changes, however, after removal of LCMS artefacts
and known contaminants, the only reproducible change (,3-fold)
amongst the unidentified peaks was the appearance of
C10H15N3O3S (mass=257.0834, RT=13.5) in the nifurtimox-
treated cells. This mass is in agreement with the saturated open
chain nitrile metabolite of nifurtimox.
Results
Eflornithine and other trypanostatic compounds
antagonise nifurtimox activity
The IC50 of eflornithine on bloodstream form cells in vitro was
35 mM using a standard alamar blue assay [23]. The IC50 of
nifurtimox was 4 mM (Table 1). The drugs were widely believed to
be synergistic given the fact that eflornithine ultimately diminishes
polyamine production and in turn production of trypanothione,
the trypanosome’s principal anti-oxidant, whilst nifurtimox had
been proposed to generate oxidative stress [6,7]. However, we
showed in isobologram analyses that the action of nifurtimox and
eflornithine did not synergise when nifurtimox action was assayed
in the presence of several fixed concentrations of eflornithine [13]
and Fig. 1A. Indeed, an antagonistic effect was seen with a
fractional inhibitory concentration of 1.61.
To determine the levels at which eflornithine is cytostatic and
cytotoxic, time course assays were conducted with drug at various
concentrations (Fig. 1B). Eflornithine was found to be cytostatic (cells
remained at the same density even at 500 mM until around 55 hours
in drug, when they died). There was no overt sign of differentiation
to stumpy forms, but as the 427 strain is monomorphic, and thus
incapable of the morphological changes associated with differenti-
ation in field isolates, this would not be expected. Nifurtimox, on the
other hand, had lysed alltrypanosomes by8 hours in60 mMd r u g .I t
is possible that eflornithine’s antagonistic effect could relate to its
cytostatic potential, if, for example, nifurtimox activity depends on
cellular proliferation.
The purine analogues, NA42 and NA134 are also known to be
cytostatic [32] and these compounds were tested in combination
with nifurtimox and also found to be antagonistic with FICs
(fractional inhibitory concentrations) of 1.40 and 1.56 for NA42
and NA134 respectively. DB75, a known potent trypanocidal
agent [33], on the other hand, was shown to be additive in its
activity with nifurtimox (FIC: 1.09).
Eflornithine induced perturbation to the T. brucei
metabolome
In order to detect molecular targets of eflornithine, a first
experiment using sub-lethal levels (20 mM) of drug was used, with
the cellular metabolome measured at 0, 1, 24, 48 and 72 hours
following exposure to drug. Eflornithine was added to the 427
bloodstream form wild type cell line in the same growth medium
Table 1. Trypanocide activities in vitro and in HAT treatment.
Trypanocide Bloodstream form in vitro IC50 Human treatment
Eflornithine 35 mM[ 1 3 ]( T. b. b)
3.35 mg/ml [26] (T. b. r)
0.33 mg/ml [26] (T. b. g)
56 infusions over 14 days [1].
Nifurtimox 4 mM[ 1 3 ]( T. b. b)
3.37 mM [44] (T. b. b)
3 times a day oral tablet for 10 days (only available in combination
with eflornithine, 14 infusions over seven days) [52].
Pentamidine 43 nM [13] (T. b. b)
0.2 ng/ml [26] (T. b. r)
0.3 ng/ml [26] (T. b. g)
4 mg/kg daily for 7–10 days [53].
Suramin 4.6 nM [13] (T. b. b)
19.9 ng/ml [26] (T. b. r)
453 ng/ml [26] (T. b. g)
5 injections of 1 g every 3–7 days for 28 days [54].
Melarsoprol 4.3 nM [13] (T. b. b)
1.7 ng/ml [26] (T. b. r)
0.9 ng/ml [26] (T. b. g)
2.2 mg/kg daily for 10 days [1].
IC50sf o rT. b. brucei (T. b. b), T. b. rhodesiense (T. b. r)a n dT. b. gambiense (T. b. g) are shown.
doi:10.1371/journal.pntd.0001618.t001
Trypanocide Modes of Action by Metabolomics
www.plosntds.org 3 May 2012 | Volume 6 | Issue 5 | e1618in which IC50 values had been determined, so that cells were
metabolising as normal apart from the perturbation by the drug.
The stringent filtering systems in the mzMatch and IDEOM
software reduced the number of peaks in the spectra from several
hundred thousand to a few hundred robust signals with putative
metabolite identities (Fig. S1). Most metabolite levels were
unaltered over the time points taken, indicating a high level of
robustness within the trypanosome metabolome. Ornithine (mass:
132.0899, RT: 27.9 minutes), the substrate of eflornithine’s known
target, ornithine decarboxylase (ODC), was the most significantly
modulated metabolite over the time course (7.5 fold increased at
48 hours). Putrescine (mass: 88.1001, RT: 36.91 minutes), the
product of the ODC reaction was the only known metabolite in
the T. brucei metabolite database at KEGG, to significantly
decrease (by 66% at 48 hours) over time. Acetylated ornithine
and putrescine were also detected, and these correlated highly
with their non-acetylated counterparts. N-acetyl ornithine (mass:
174.1004, RT: 15.3 minutes) showed the most striking correlation.
N-acetyl-putrescine (mass: 130.1106, RT: 15.5 minutes) was seen
in early samples, but levels rapidly fell below the level of detection
(1,000) from an average intensity of 41,000 (peak height) before
drug addition, correlating with the decrease in putrescine.
Cells were also treated with 500 mM eflornithine, a lethal dose
of the drug. At this dose bloodstream form trypanosomes exhibit
division arrest over 48 hours in drug before dying between 48 and
55 hours (Fig. 1B). This was reflected by many more changes to
the metabolome (Figure S2). Changes to polyamine pathway
metabolites were again consistent with inhibition of ODC, with
significant increases in ornithine and N-acetyl ornithine, and
decreases in putrescine and N-acetyl putrescine, observed within
5 hours and maintained for the duration of treatment. Spermidine
was significantly decreased by 24 hours, confirming the down-
stream effect of ODC inhibition on polyamine levels (Fig. 2).
Additional metabolites that significantly increased within 24 hours
were putatively identified as N-acetyl spermidine, N-acetyl lysine
and N5-(L-1-Carboxyethyl)-L-ornithine (a known bacterial me-
Figure 1. Analysis of eflornithine and nifurtimox on T. brucei growth. A) The effects of trypanostatic drugs in combination with nifurtimox.
White points show the drugs in combination, black points show the drugs in isolation. FICs are 1.61 for eflornithine, 1.40 for NA42, 1.56 for NA134 and
1.09 for DB75 on nifurtimox action and 1.22 for nifurtimox on eflornithine action. Error bars show the standard error of the mean. N=at least 3. B)
Growth curves of T. brucei in eflornithine (top) and nifurtimox (bottom). White points show no drug, grey shows half IC50 and black shows growth in
toxic doses (500 mM eflornithine, 60 mM nifurtimox).
doi:10.1371/journal.pntd.0001618.g001
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in a position to rule out its generation as a non-enzymatic liaison
between these chemicals during sample preparation). These
metabolites, along with N-acetyl ornithine, demonstrate metabolic
derivitisation of ornithine and other polyamine metabolites, which
may be an upregulated process in response to the elevated
ornithine levels.
Aside from the polyamines, most major decreases in metabolite
levels over 24 hours were observed among the phospholipids.
Polyamines have previously been shown to be key mediators of
membrane stability [34–36], and the lipid degradation observed
here is consistent with cell membranes being compromised by
polyamine depletion. Furthermore, the majority of metabolites in
the cell decrease at the 48 hour time point, indicating a possibility
that the cell membranehasbeen compromisedand metabolitesmay
be leaking from the cell during incubation and/or sample
preparation. The processing of the cells involves cooling them to
0uC in a dry ice–ethanol bath and two centrifugation steps. These
weakened cells are therefore potentially more leaky than cells that
have not been compromised by prolonged exposure to eflornithine.
Several methionine-related metabolites (cystathionine, S-ade-
nosyl methionine, methylthioadenosine and methyl-methionine)
increased over the first five hours in drug, which was not reported
in previous studies. S-adenosyl methionine is the aminopropyl
donor involved in spermidine synthesis, and it is possible that this
pathway has been upregulated in response to the declining
polyamine levels. Methionine levels do not increase over this time
course, however, this may be due to the high concentration of
methionine in the growth medium (200 mM) and robust transport
[37] masking any changes within the cells.
Despite the significant decrease observed for spermidine, levels
of trypanothione disulphide were not affected during the first
24 hours of treatment. A significant decrease was observed at
48 hours. The analytical platform used here is not capable of
reporting the oxidation state of trypanothione or other thiols.
The other significant changes observed during the first 24 hours
of eflornithine treatment were not expected. Sedoheptulose (mass:
210.0738, RT: 14.9 minutes) and sedoheptulose phosphate (mass:
290.0400, RT: 25.4 minutes) were increased, as well as a
metabolite with the chemical formula C7H12O5 (mass: 176.0683,
Figure 2. Polyamine pathway and metabolite changes after addition of toxic (500 mM) dose of eflornithine. X-axes indicate the time in
hours since eflornithine addition. Y-axes indicate the raw abundance of each metabolite signal. Results show mean and standard deviation of 3
replicates.
doi:10.1371/journal.pntd.0001618.g002
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possibly diacetylglycerol or another isomer.
Sources of ornithine in T. brucei
Our metabolomics analysisabove reveals ODC tobe the primary
target of eflornithine, as was already clear based on previous work
and the design of the compound as a specific inhibitor of the
enzyme. Surprisingly, however, we could find no previous work that
has focused on the cellular source of ornithine in T. brucei. In many
eukaryotes, ornithine is produced from arginine via the enzyme
arginase. In Leishmania parasites, which belong to the same
taxonomic group as T. brucei, for example, an arginase enzyme has
beencharacterisedinsome detail[38–41].T.brucei,however,lacksa
gene that is syntenic with the known Leishmania arginase. A second
gene related to arginase is present in Leishmania and an orthologue
is present in T. brucei (Tb927.8.2020). This latter predicted enzyme,
however, lacks key arginase residues and is currently annotated as a
putative agmatinase (although this also seems unlikely given the lack
of conservation of key active site residues). We measured arginase
activity in Leishmania mexicana extracts and compared this to T. brucei
extracts where we show that the trypanosome contains little or no
classical arginase activity when compared to Leishmania (Fig. 3A).
The absence of a classical arginase raises questions about other
potential sources of ornithine in T. brucei. Our experiments did
reveal the presence of N-acetyl ornithine in T. brucei, the abundance
of which was closely correlated to ornithine. Differences in the
retention times between ornithine (RT=27.9 minutes) and acet-
ylornithine (RT=15.3 minutes) confirm that the two metabolites
are not mass spectrometry artefacts. In a variety of bacteria
ornithine is produced from glutamate in a pathway that involves N-
acetyl ornithine as an intermediate [42,43].
We used heavy-nitrogen labelled metabolites to trace whether a
similar pathway exists in T. brucei. However, cells incubated with
isotopically-labelled extracellular
15N-glutamate failed to accumu-
late this amino acid to a detectable level. We therefore provided
15N labelled glutamine, which was converted to glutamate (albeit
at a relatively low level of 5% of the non-labelled metabolite) after
two hours and
15N-proline which was converted to glutamate at
levels of 3.1% of the unlabelled glutamate generated within these
cells. However, the heavy atom labelled glutamate was not further
converted to ornithine, N-acetyl ornithine or N-acetyl glutamate
semialdehyde (another metabolite of the glutamate to ornithine
pathway). Furthermore, no orthologues, other than N-acetyl
ornithine deacetylase (Tb927.8.1910), encoding enzymes of the
bacterial pathway could be identified in the trypanosome genome
indicating that this pathway is not operative in trypanosomes.
Although ornithine is not a component of HMI-9 medium,
metabolomics analysis of our medium indicated that the
commercial supply we used did contain ornithine and we were
able to measure its concentration at 77 mM, using a calibration
curve with isotopically labelled ornithine. We therefore measured
the ability of
3H-ornithine to enter trypanosomes. This indicated a
possible external source of ornithine and we tested the ability of
this nutrient to enter trypanosomes. At 10 mM, ornithine was
shown to enter bloodstream form T. brucei at a rate of
approximately 10 pmol/10
7 cells/min (Fig. 3B). Kinetic analysis
of ornithine transport indicated a Km of 310 mM and Vmax of
15.9 pmol/10
7 cells/min (Fig. 3C). Given that ornithine is present
in serum and cerebrospinal fluid (at concentrations of 54–100 mM
in plasma and 5 mM in CSF (according to the human metabolome
database, http://www.hmdb.ca/)), this would indicate that T.
brucei is capable of fulfilling its ornithine requirements directly by
transport from the bodily fluids in which it resides. When we used
15N-ornithine externally to trace its metabolism we showed that N-
acetyl ornithine, spermidine and trypanothione disulphide when
added to cells growing in HMI-9.
15N-labelled arginine was
converted to ornithine when administered in CBSS (Carter’s
balanced saline solution), but not when administered in HMI-9
growth medium. This suggested that when exogenous ornithine is
present, uptake of ornithine is sufficient for polyamine synthesis,
but when absent, synthesis from arginine is possible. This was
confirmed by the addition of exogenous ornithine in addition to
heavy arginine in CBSS, where synthesis of heavy ornithine from
arginine was no longer detected (heavy ornithine being present at
40% of unlabelled ornithine levels when exogenous ornithine was
not added under the same conditions). The enzymatic route by
which arginine is converted to ornithine in the absence of
canonical arginase is not known.
Nifurtimox induced changes to the trypanosome’s
metabolome
At the sub-lethal dose of 1.5 mM nifurtimox, no significant
changes to the metabolome were recorded (data not shown).
However,ata lethaldose of60 mMchangestothe metabolome at0,
1, 2 and 5 hours following exposure to drug, were seen (Figure S3).
Nifurtimox (mass: 287.0577, RT: 5.25 minutes) was observed in all
treated samples, in addition to a mass (mass: 257.0834, RT:
13.5 minutes) consistent with the saturated open chain nitrile
metabolite [11] (Fig. 4A) which was recently shown to be the end
product ofthemulti-step 2-electron reductionofnifurtimox bytype-
1 nitroreductase. Previous work in a cell-free system showed the
saturated nitrile only after 24 hours of drug exposure to the
nitroreductase [11]. Our metabolomics platform allows identifica-
tion of this metabolite within the cell, and shows the process to be
rapid withsignificant levels detectable at the first, 1 hour timepoint.
The implicit intermediates from this reductive activation cascade,
including the unsaturated open chain nitrile proposed to mediate
trypanocidal activity, were not observed, indicating either that the
reductionis rapid and intermediates in the pathway do not persistat
detectable concentrations, or that the reactive intermediates indeed
react rapidly with intracellular macromolecules. An exhaustive
search of all known metabolites in our database revealed no
detectable masses that correspond to a hypothetical adduct between
the unsaturated open chain nitrile and any known metabolite. Our
metabolomics platform, by definition, was unable to detect the
potential formation of adducts between nifurtimox metabolites and
macromolecules (proteins or nucleic acids).
A number of cellular metabolites were shown to change in
abundance over the nifurtimox exposure time course (Table 2),
although 95% of putatively identified metabolites were stable.
There was an increase in concentrations of nucleotides and
nucleobases (adenine, deoxyadenosine, AMP, GMP, uracil and
UMP) during the time course, which may result from degradation
of RNA and DNA consistent with the hypothesis [11] that the
nifurtimox active metabolite (the open chain nitrile) binds to
macromolecules including nucleic acids, by the ability of the
unsaturated nitrile intermediate to act as a Michael acceptor [11].
Glycolysis appeared to be downregulated, with significant
decreases in hexose 6-phosphates, and similar trends for glyceral-
dehyde 3-phosphate and 3-phosphoglycerate. The metabolite that
decreased most following nifurtimox treatment was deoxyribose,
which may indicate reduced synthesis from the glycolytic interme-
diates, or could be related to nucleic acid homeostasis. Lipid
metabolism was largely unaffected with the exception of decreased
levels of monounsaturated ether-linked lysophosphatidylcholines
(14:1, 15:1 and 16:1) and ethanolamine phosphate.
Metabolites of the polyamine pathway were not significantly
altered over the nifurtimox time course, although decreased thiol
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phide) were observed, suggesting that oxidative stress may be
induced on exposure to nifurtimox in agreement with previous
studies [6,7,44], although the role of this stress in ultimate
trypanocidal effect is uncertain. It is noted that this untargeted
metabolomics approach is not suited for assessment of redox
balance (as reduced thiols are oxidised during sample preparation
and analysis), however and it is assumed that the observed
disulphide levels are indicative of total thiol levels. The presence
of oxidative stress may also explain the observed inhibition of
glycolysis [45], and the decreased levels of arginine phosphate [46].
NECT induced perturbations to the trypanosome’s
metabolome
We also investigated changes to the metabolome associated with
exposure to eflornithine and nifurtimox simultaneously (Figure
S4). The metabolome of NECT treated cells was measured using
drug levels that were toxic in the monotherapies (500 mM for
eflornithine and 60 mM for nifurtimox) and the time points used in
the nifurtimox toxicity assay (0, 1, 2 and 5 hours), after which cells
died without remaining viable for as long as studied in the
eflornithine monotherapy study. The rapid reduction of Nifurti-
mox (within 1 hour) to the saturated open chain nitrile was still
Figure 3. Ornithine uptake may be sufficient for polyamine synthesis. A) Arginase activity in L. mexicana and T. b. brucei cell extracts. One
unit is equivalent to 1 mmole of arginine converted to ornithine and urea per minute at pH 9.5 and 37uC. N=at least 3. Results show mean 6 S.E.M. B)
Ornithine uptake at 20 mM over time in T. b. brucei. N=4. C) Kinetics of the ornithine transporter in bloodstream form T. b. brucei. Km: 310 mM, Vmax:
15.9 pmol/min/10
7 cells. Results show mean 6 S.E.M, N=4.
doi:10.1371/journal.pntd.0001618.g003
Figure 4. Nifurtimox metabolism to saturated open chain nitrile. Purple triangles=NECT, Blue circles=Nifurtimox. Nifurtimox (A) (Mass:
287.0576, RT: 5.4 minutes) is reduced, through a number of steps to a saturated open chain nitrile (B) (Mass: 257.0834, RT: 13.5 minutes). Neither
metabolite is detected at the 0 time point (where no drug is added). N=3. Error bars show standard deviations.
doi:10.1371/journal.pntd.0001618.g004
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known to be responsible for metabolic activation of nifurtimox
[11] is not diminished in a short term response to eflornithine.
The combination therapy showed qualitatively most of the same
changes that were present in each of the monotherapies alone
(Table 2 and Fig. 5). This indicates that both of the drugs are able
to exert their individual effects and no additional effects were
apparent using the combination. The eflornithine-induced chang-
es to polyamine pathway metabolites were observed in the
combination (Fig. 2), although the later effects of eflornithine
could not be measured as cells died from nifurtimox toxicity before
these were apparent. The nifurtimox-induced changes to nucle-
otides, glycolysis intermediates, deoxyribose and thiols were all
observed to a similar extent in the combination treatment.
Discussion
Understanding how small chemicals interfere with cellular
metabolism is a critical part of modern drug development. Here
we show how a relatively simple LC-MS based metabolomics
platform can be used to identify drug modes of action in the
causative agent of human African trypanosomiasis, Trypanosoma
brucei. Using each of the drugs currently used in combination as a
first line treatment against stage two HAT we reveal how modes of
action of drugs can be rapidly ascertained.
At low levels of drug (sub IC50) specific changes to the
metabolome can be detected as was evidenced with eflornithine.
The data reveal very localised changes to the metabolome with little
indication of broadly disseminated affects consistent with the theory
that metabolic networks are generally robust to perturbations [47].
This study reveals the power of metabolomics for predicting the
MOA of compounds with a metabolic (enzyme inhibition) mode of
action. As ornithine accumulation and putrescine loss were the most
significant changes between treated and untreated cells, ornithine
decarboxylase emerges as the most likely target for this drug. In
this case, the outcome was already known hence the follow up
experiments e.g. showing that ODC is essential using gene knockout
[48] and that addition of polyamines to the medium can bypass
eflornithine toxicity [48] have already been performed. With
unknown drugs, of course, these validation experiments are still
required once the hypothesis has been set using metabolomics. The
presence of the open chain trinitrile in nifurtimox-treated cells
confirms the trypanosome-mediated metabolic activation of thisdrug,
as was recently demonstrated following substantial targeted analysis
of nifurtimox [11]. It will be of interest to extend studies to other
current trypanocides and also to systematically include metabolomics
in any test of action for compounds emerging from screens.
Eflornithine inhibited ODC relatively quickly with levels of
ornithine and putrescine demonstrably altered after just five hours in
toxic doses of drug. Trypanothione is a glutathione-spermidine
adduct and its overall levels are diminished by around 73% prior to
death in the eflornithine study, which is similar to the 66% reduction
determined after eflornithine exposure in vivo [10], but it should be
noted that many unrelated metabolites were also diminished at
48 hours. An advantage of the non-targeted metabolomics platform
used here over a strictly targeted approach to report on individual
metabolites is thus clear. Loss of putrescine and spermidine appears
to contribute to cellular toxicity independently of their role in
trypanothione biosynthesis as rescue experiments where spermidine
is given exogenously to ODC knock down cells were unsuccessful
[49]. Our studies indicate that eflornithine is trypanostatic for
48 hours, before killing the parasites after apparently compromising
the membrane of the cell, as judged by a general loss of metabolites
from the cell and particularly changes in lipid content. Since
polyamines have been proposed to help stabilise membrane
phospholipids [34,35] this could indicate the actual cause of death
following reduction in polyamine biosynthesis. In vivo, changes to
membrane integrity would also expose new ligands to the immune
systems, possibly explaining the need of an active immune system for
optimal eflornithine activity [47]. Nifurtimox did not show the same
depletion in membrane integrity prior to cell death.
The untargeted metabolomics approach was particularly useful for
theidentificationof unexpected metabolites. Acetylated ornithine and
putrescine have not been previously described in trypanosomes, and
would likely not have been assessed with a classical targeted
approach, but these results clearly show the presence of acetylated
polyamines, and their dynamic relationships with polyamine levels,
with N-acetyl ornithine correlating particularly well with ornithine.
This metabolite has an unknown function within trypanosomes but
appearstobecreateddirectlyfromornithine transportedintothecell.
We have also shown that trypanosomes do not use classical arginase
activity comparable to that found in related Leishmania spp. parasites
to create ornithine from arginine but do have the ability to transport
ornithine which is present in plasma and CSF, indicating that they
probably fulfil ornithine needs by acquiring it directly from the host.
Interestingly they can, nevertheless, convert arginine to ornithine, but
apparently only when exogenous ornithine is not available.
An increase in sedoheptulose and sedoheptulose phosphate in
eflornithine-treated cells was also of interest. Sedoheptulose
phosphate is a seven carbon sugar of the pentose phosphate
pathway, formed, along with glyceraldehyde 3-phosphate, from
Table 2. Changes in metabolite abundance (relative
intensity) induced by 5 hours of eflornithine, nifurtimox and
NECT treatment expressed relative to untreated levels.
Ratio 5:0 hours
Name Eflornithine Nifurtimox NEC
Ornithine 5.62 1.11 2.97
Acetylornithine 3.2 0.93 1.21
Cystathionine 2.99 1.09 1.13
Methylthioadenosine 2.38 1.11 2.06
S-adenosyl methionine 3.83 1.03 1.72
Putrescine 0.07 0.95 0.16
Acetylputrescine 0.37 0.94 1.52
Trypanothione disulphide 1.32 0.59 0.32
Arginine phosphate 0.83 0.47 0.52
Uracil 0.98 2.62 1.93
UMP 0.74 2.18 1.68
Adenine 1.23 5.01 6.06
AMP 0.97 3.61 3.00
GMP 1.33 1.52 1.25
Hexose phosphates
(average of isomeric peaks)
1.31 0.56 0.72
3-Phosphoglycerate 1.29 0.63 0.44
Glyceraldehyde 3-phosphate 1.26 0.67 0.67
Deoxyribose 0.82 0.41 0.18
Peptides (average) 1.27 0.97 1.2
Lipids (average) 1.07 1.1 1.0
Bold numbers indicate a significant change according to the student’s T-test
(a=0.05).
doi:10.1371/journal.pntd.0001618.t002
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(Tb927.8.6170) action. Transketolase activity, however, is absent in
bloodstream-form trypanosomes [50,51], although it is induced in
parasites transforming between bloodstream and procyclic forms. It
is possible,therefore,that the increase insedoheptulose 7-phosphate
could relate to transketolase being switched on in relation to the
proposed induction of differentiation between slender bloodstream
form and stumpy form organisms. Although the s427 strain used
here does not differentiate to stumpy forms, other biochemical
events such as the induction of enzymes usually repressed in the
non-dividingstumpystage mayoccur. Nifurtimox treatmentdidnot
induce any changes to sedoheptulose or its phosphate’s levels.
Toxic doses of nifurtimox revealed alterations to levels of
various nucleotide, carbohydrate and lipid metabolites. More work
is required to ascertain why these metabolites’ levels are altered
with nifurtimox treatment and how these changes relate to death.
However, our data reveal that this metabolomics approach can
confirm previous findings that relate oxidative stress to nifurtimox
treatment, and demonstrate the production of an open chain
trinitrile metabolite in agreement with the proposed mechanism
for the drug’s selective activity against trypanosomes [11]. We
show also that the appearance of this metabolite is relatively fast,
being detectable within an hour of exposure.
The nifurtimox-eflornithine combination therapy, which was
previously assumed to be synergistic, was shown to be mildly
antagonistic in vitro. The theory behind synergy was based on the
assumption that eflornithine would decease cellular trypanothione
levels thus decreasing the ability of these cells to defend against
oxidative stress. Since nifurtimox was generally believed to exert an
effect through generation of reactive oxygen species [6,7] it followed
that eflornithine treated cells would show enhanced susceptibility to
nifurtimox. However, the metabolic perturbations observed in this
study suggest that oxidative stress is not the primary MOA for either
drug (despite some indication of oxidative stress observed with
nifurtimox), and if nifurtimox actually acts through production of the
reactive open chain trinitrile and its ability to covalently modify
macromolecules, then the proposed synergy would not exist. It should
be noted too, however, that our studies in vitro need not reflect the
situation in vivo where pharmacokinetic factors lead to very different
exposure of parasites to drug and where other host related factors, not
least the immune response, contribute to effects of the drugs, although
in mice at least neither drug facilitates entry of the other into the brain.
A potential reason why the drug combination ismildlyantagonistic
in vitro could relate to the activation of nifurtimox and its target based
effects depending upon growth status of the cell. There was no
evidence that activation of nifurtimox was reduced in the eflornithine
co-treated cells. Instead, therefore, it is possible that cells entering a
state of reduced growth are less affected by the impact of nifurtimox
on energy and nucleic acid metabolism. This hypothesis was
supported by the antagonism to nifurtimox seen with the trypano-
static purine analogues NA42 and NA134 [36].
The examples we provide here demonstrate how a relatively
simple metabolomics platform can elucidate the mode of action of
a drug in a relatively short time frame. This study shows that our
metabolomics platform yields hypothesis-free data that confirm the
known MOA of eflornithine and create testable hypotheses for the
nifurtimox MOA as well as confirming a lack of synergy of NECT.
The approach we provide here can be readily adapted for other
drugs and cellular systems.
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